John Paulson’s Vanda Pharmaceuticals VNDA Stock Holding History

John Paulson’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-2,175,000	Closed	-$36.2M	–	112
2016 Q3	$36.2M	Sell	2,175,000 -1,689,717	-44%	-$22.7M	0.39%	38
2016 Q2	$43.2M	Sell	3,864,717 -62,283	-2%	-$603K	0.44%	36
2016 Q1	$32.8M	Sell	3,927,000 -19,500	-0.5%	-$160K	0.24%	45
2015 Q4	$36.7M	Hold	3,946,500	–	–	0.22%	40
2015 Q3	$44.5M	Hold	3,946,500	–	–	0.23%	47
2015 Q2	$50.1M	Sell	3,946,500 -3,500	-0.1%	-$37.7K	0.23%	43
2015 Q1	$36.7M	Buy	3,950,000 +325,000	+9%	+$3.67M	0.19%	47
2014 Q4	$51.9M	Buy	3,625,000 +375,000	+12%	+$4.44M	0.27%	45
2014 Q3	$33.7M	Buy	3,250,000 +50,000	+2%	+$655K	0.14%	59
2014 Q2	$51.8M	Buy	3,200,000 +1,807,500	+130%	+$24.1M	0.22%	60
2014 Q1	$22.6M	Buy	+1,392,500	New	+$19.8M	0.11%	69

Other funds holding VNDA

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

John Paulson's VNDA Position: Q4 2016 in Review

John Paulson sold out of Vanda Pharmaceuticals (VNDA) in Q4 2016, closing a stake of 2,175,000 shares — an estimated $36.2M sold.

John Paulson first reported a position in VNDA in Q1 2014 and held it in 11 quarters. The position peaked at $51.9M in Q4 2014. 141 funds tracked by Wall St. Rank hold VNDA as of Q4 2016.

John Paulson reported no remaining Vanda Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
John Paulson sold 2,175,000 Vanda Pharmaceuticals shares in Q4 2016, an estimated $36.2M.
John Paulson first reported a position in Vanda Pharmaceuticals in Q1 2014 and held it in 11 quarters.
John Paulson's Vanda Pharmaceuticals position peaked at $51.9M in Q4 2014.
141 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2016.

Based on Paulson & Co's 13F filing for Q4 2016, filed 14 Feb 2017.